News coverage about Teligent (NASDAQ:TLGT) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teligent earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.7840553280603 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Teligent from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Deutsche Bank AG reiterated a “hold” rating and set a $9.00 target price (up from $8.00) on shares of Teligent in a report on Monday, July 17th. BidaskClub lowered shares of Teligent from a “hold” rating to a “sell” rating in a report on Monday, July 24th. ValuEngine lowered shares of Teligent from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Finally, Canaccord Genuity assumed coverage on shares of Teligent in a research note on Monday, July 31st. They issued a “buy” rating and a $11.00 price target for the company. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $9.00.
Shares of Teligent (NASDAQ:TLGT) traded down 0.29% during trading on Friday, hitting $6.78. 101,478 shares of the company’s stock were exchanged. The stock’s market cap is $361.99 million. Teligent has a one year low of $5.75 and a one year high of $8.06. The firm has a 50-day moving average price of $6.84 and a 200-day moving average price of $7.01.
Teligent (NASDAQ:TLGT) last issued its earnings results on Tuesday, August 8th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.04). The company had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $20.11 million. Teligent had a positive return on equity of 1.49% and a negative net margin of 11.36%. Teligent’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.02 earnings per share. Equities research analysts expect that Teligent will post $0.07 EPS for the current fiscal year.
Teligent Company Profile
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with our FREE daily email newsletter.